Literature DB >> 17546829

Benign prostatic hyperplasia: when to 'watch and wait,' when and how to treat.

Albert Levy1, George P Samraj.   

Abstract

Benign prostatic hyperplasia (BPH) is a clinical diagnosis. While BPH is a common cause of lower urinary tract symptoms (LUTS) in men, LUTS can signify a number of other disease states. For this reason, the patient evaluation, which includes a digital rectal examination, and careful differential diagnosis are crucial in men with LUTS. Many men with BPH are asymptomatic, and many others are not bothered by their symptoms; watchful waiting is appropriate management for these patients. When symptoms affect quality of life, pharmacologic therapy should be an option; choices include an alphablocker, a 5 alpha-reductase inhibitor, or, for men with larger prostates, a combination of the two. Surgical intervention is indicated when BPH leads to other medical complications, including urinary retention and renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17546829     DOI: 10.3949/ccjm.74.suppl_3.s15

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  9 in total

Review 1.  The evaluation and treatment of prostate-related LUTS in the primary care setting: the next STEP.

Authors:  Matt T Rosenberg; David Staskin; John Riley; Grannum Sant; Martin Miner
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

2.  Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up.

Authors:  Joao Martins Pisco; Hugo Rio Tinto; Luís Campos Pinheiro; Tiago Bilhim; Marisa Duarte; Lúcia Fernandes; José Pereira; António G Oliveira
Journal:  Eur Radiol       Date:  2013-01-31       Impact factor: 5.315

3.  Diagnosis and management of benign prostatic hyperplasia in primary care.

Authors:  Simon Tanguay; Murray Awde; Gerald Brock; Richard Casey; Joseph Kozak; Jay Lee; J Curtis Nickel; Fred Saad
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

4.  Long-Term Follow-Up Results of Photoselective Vaporization of the Prostate with the 120 W Greenlight HPS Laser for Treatment of Benign Prostatic Hyperplasia.

Authors:  Se-Hee Kang; Yong Sun Choi; Su Jin Kim; Hyuk Jin Cho; Sung-Hoo Hong; Ji Youl Lee; Tae-Kon Hwang; Sae Woong Kim
Journal:  Korean J Urol       Date:  2011-04-22

5.  Is absorption of irrigation fluid a problem in Thulium laser vaporization of the prostate? A prospective investigation using the expired breath ethanol test.

Authors:  Livio Mordasini; Dominik Abt; Gautier Müllhaupt; Daniel S Engeler; Andreas Lüthi; Hans-Peter Schmid; Christoph Schwab
Journal:  BMC Urol       Date:  2015-04-24       Impact factor: 2.264

Review 6.  Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update.

Authors:  Fouad Aoun; Quentin Marcelis; Thierry Roumeguère
Journal:  Res Rep Urol       Date:  2015-08-19

7.  Twelve-Month Follow-up Results of Photoselective Vaporization of the Prostate With a 980-nm Diode Laser for Treatment of Benign Hyperplasia.

Authors:  Youngho Kim; Youl Keun Seong; In Gon Kim; Bo Hyun Han
Journal:  Korean J Urol       Date:  2013-10-15

8.  Prostatic artery embolization versus conventional TUR-P in the treatment of benign prostatic hyperplasia: protocol for a prospective randomized non-inferiority trial.

Authors:  Dominik Abt; Livio Mordasini; Lukas Hechelhammer; Thomas M Kessler; Hans-Peter Schmid; Daniel S Engeler
Journal:  BMC Urol       Date:  2014-11-25       Impact factor: 2.264

9.  An Updated Meta-Analysis of the Efficacy and Safety of Prostatic Artery Embolization vs. Transurethral Resection of the Prostate in the Treatment of Benign Prostatic Hyperplasia.

Authors:  Zhunan Xu; Zhongbao Zhou; Yingmei Mu; Tong Cai; Zhenli Gao; Lingling Liu
Journal:  Front Surg       Date:  2021-12-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.